Probi's clinical studies fall short

Preliminary analyses shows that the results of the gut and immune health studies did not meet expectations.

The results from Probi’s two clinical studies conducted in 2012, one in immune health and one in gut health, are now available. Preliminary analyses of the data show that the results from the studies did not meet expectations. Probi will consequently not apply to the European Food Safety Authority (EFSA) for health claims within the EU at this point.

”We have gained important new knowledge from the studies and the data will now be analysed in more detail to guide continued clinical development within immune and gut health, areas where we have previously demonstrated very good results”, says Michael Oredsson, CEO of Probi.


Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.